Zonisamide as treatment option in persistent migraine aura.
drugs: CNS (not psychiatric)
headache (including migraines)
Journal
BMJ case reports
ISSN: 1757-790X
Titre abrégé: BMJ Case Rep
Pays: England
ID NLM: 101526291
Informations de publication
Date de publication:
12 Apr 2021
12 Apr 2021
Historique:
entrez:
13
4
2021
pubmed:
14
4
2021
medline:
15
5
2021
Statut:
epublish
Résumé
Persistent migraine aura without infarction is a rare but debilitating condition. Treatment options are mostly anecdotal and limited due to inefficacy and side effects. We present a 16-year-old female patient with triple X syndrome, having persistent aura symptoms for over 2 years, consisting of continuous visual and sensory sensations. Previous treatments with seven different migraine preventatives were not successful. The patient successfully responded to zonisamide against refractory prolonged aura and remained symptom-free under the ongoing treatment without any relevant side effects. Zonisamide may be considered a new and safe treatment option for patients with persistent migraine aura.
Identifiants
pubmed: 33846185
pii: 14/4/e240783
doi: 10.1136/bcr-2020-240783
pmc: PMC8048010
pii:
doi:
Substances chimiques
Zonisamide
459384H98V
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© BMJ Publishing Group Limited 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: KK received travel grants from Novartis and Eli Lilly. FF received travel grants from Novartis, Teva and Eli Lilly, and is a recipient of a grant from the Austrian Academy of Sciences (ÖAW). GB received unrestricted grants, honoraria, personal fees and travel grants from Allergan, Amgen, Menarini, Pfizer, Linde AG, AstraZeneca, St Jude Medical, Reckitt Benckiser, Novartis, Teva, Fresenius, Janssen-Cilag, Eli Lilly, Österreichische Gesellschaft für Neurologie, European Headache Federation, Österreichische Kopfschmerzgesellschaft, ÖAW and European FP7 framework programme.
Références
Cephalalgia. 2018 Jan;38(1):1-211
pubmed: 29368949
Neurology. 1997 Jan;48(1):261-2
pubmed: 9008529
Iran Red Crescent Med J. 2016 Apr 30;18(9):e23768
pubmed: 28144450
Clin Neuropharmacol. 2011 Jul-Aug;34(4):174-7
pubmed: 21738025
Clin Neuropharmacol. 2009 Mar-Apr;32(2):103-6
pubmed: 18978487
Headache. 2014 Sep;54(8):1290-309
pubmed: 24863140
Eur J Hum Genet. 2010 Mar;18(3):265-71
pubmed: 19568271
Headache. 2001 Sep;41(8):823-5
pubmed: 11576209
Curr Treat Options Neurol. 2019 Mar 18;21(4):16
pubmed: 30880369
Headache. 2016 Sep;56(8):1373-9
pubmed: 27400397
Neurology. 2000 Sep 12;55(5):732-3
pubmed: 10980751